updat model reflect guidanc although consensu toward
high-end guid think reflect solid underli growth without
number tailwind expect reoccur on-going migrat
cost associ fusion guid would higher notabl macro
environ appear stabil improv
adj ep guidanc reflect solid underli growth particularli
assum number tailwind reoccur better expect
healthcar cost amount tailwind expect reoccur
addit earlier expect vaccin sale result pullforward
tax anoth headwind tax rate
benefit discret item higher mix foreign-bas incom lastli
guidanc would higher anoth transit year lash
fusion migrat expect weigh sg fiscal year recal without
headwind due fusion implement segment oper incom growth
would double-digit rather high-singl digit anoth factor
consid weigh adj ep guidanc includ unidentifi
capit alloc guidanc mean share count guidanc assum
share repurchas estim share repurchas would contribut
increment adj ep guidanc
similar commentari peer drug distribut management comment earn
call indic underli macro fundament stabl notabl management state
earn call brand inflat gener price environ
expect similar level seen specif see stabil
buy-sid gener price environ expect sell-sid price environ
continu competit stabl
lower adj ep estim
respect reflect management guidanc includ share repurchas
note past two fiscal year repurchas share
slightli lower price target base revis dcf analysi
impli share trade adj ep estim dcf
analysi impli slightli lower price target due work capit headwind impli
guidanc rel
pleas see page report import disclosur
posit believ share trade attract multipl particularli
fundament core pharma distribut stabil also view
lead posit specialti favor addit see potenti upsid
pharmedium acceler growth segment beyond mwi
lash expect becom meaning contributor
resolut opioid litig
updat strateg financi
review pharmedium
almost top-lin growth driven
specialti esrx onboard ci
gross margin
ebit margin
top-lin growth doubl digit
due greater expect growth
gross margin approach due
better expect mix gener
sg better expect due
share come lower due greater
expect share repo
top-lin growth mid-singl digit
due slower expect growth
margin closer due higher
sg come wors expect
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
million except per-shar data
cowen compani
changevariancetot cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu distributiontot chang basi earn basi servicesoth chang basi earn basi cowen
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt recov expens current charg total liabil account payabl current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti equipment- impair charg equiti investment- lifo pension settlement- includ intang asset loss earli retir chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash proce sale properti equipment- equiti proce sale business- purchas invest secur avail sale- net cash provid use invest activ continu net cash provid use invest activ discontinu ops- net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri payment premium earli retir debt- defer financ cost other- exercis warrants- exercis stock dividend common purchas cap call net cash provid use financ activ continu net cash provid use financ activ discontinu op net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number risk associ pt includ lower expect brand
inflat higher expect brand inflat loss signific custom
higher expect litig expens and/or settlement relat opioid
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
